We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ibex Technologies Inc (IBT) NPV

Sell:1.43 CAD Buy:1.44 CAD Change: No change
Market closed |  Prices as at close on 26 March 2024 | Switch to live prices |
Sell:1.43 CAD
Buy:1.44 CAD
Change: No change
Market closed |  Prices as at close on 26 March 2024 | Switch to live prices |
Sell:1.43 CAD
Buy:1.44 CAD
Change: No change
Market closed |  Prices as at close on 26 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.

Contact details

Address:
Suite 100, 5485 Pare Street
MONTREAL
H4P 1P7
Canada
Telephone:
+1 (514) 3444004
Website:
https://www.ibex.ca/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IBT
ISIN:
CA4489375085
Market cap:
35.05 million CAD
Shares in issue:
24.51 million
Sector:
Biotechnology
Exchange:
Canadian Venture Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Paul Baehr
    Chairman of the Board, President, Chief Executive Officer
  • Belinda Franco
    Vice President - Finance and Administration
  • Mahendra Pallapothu
    Vice President - Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.